Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Larimar Therapeutics (LRMR) Other Operating Expenses (2019 - 2020)

Larimar Therapeutics (LRMR) has disclosed Other Operating Expenses for 2 consecutive years, with -$5.6 million as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Other Operating Expenses changed N/A year-over-year to -$5.6 million, compared with a TTM value of -$8.6 million through Dec 2019, changed N/A, and an annual FY2019 reading of -$5.6 million, up 88.04% over the prior year.
  • Other Operating Expenses was -$5.6 million for Q4 2019 at Larimar Therapeutics, down from -$3.0 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at -$3.0 million in Q2 2019 and bottomed at -$5.6 million in Q4 2019.